DE69232859T2 - Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden - Google Patents

Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden

Info

Publication number
DE69232859T2
DE69232859T2 DE69232859T DE69232859T DE69232859T2 DE 69232859 T2 DE69232859 T2 DE 69232859T2 DE 69232859 T DE69232859 T DE 69232859T DE 69232859 T DE69232859 T DE 69232859T DE 69232859 T2 DE69232859 T2 DE 69232859T2
Authority
DE
Germany
Prior art keywords
composition
virus polypeptides
several immune
immune reactive
reactive hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232859T
Other languages
English (en)
Other versions
DE69232859D1 (de
Inventor
J Weiner
Michael Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25056174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69232859(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE69232859D1 publication Critical patent/DE69232859D1/de
Publication of DE69232859T2 publication Critical patent/DE69232859T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
DE69232859T 1991-09-13 1992-09-11 Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden Expired - Lifetime DE69232859T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75957591A 1991-09-13 1991-09-13
PCT/US1992/007683 WO1993006126A1 (en) 1991-09-13 1992-09-11 Immunoreactive hepatitis c virus polypeptide compositions

Publications (2)

Publication Number Publication Date
DE69232859D1 DE69232859D1 (de) 2003-01-16
DE69232859T2 true DE69232859T2 (de) 2003-04-10

Family

ID=25056174

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232859T Expired - Lifetime DE69232859T2 (de) 1991-09-13 1992-09-11 Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden

Country Status (16)

Country Link
US (6) US5756312A (de)
EP (1) EP0608261B1 (de)
JP (5) JPH06511149A (de)
AT (1) ATE228564T1 (de)
AU (1) AU679429B2 (de)
BG (1) BG62973B1 (de)
CA (1) CA2116764C (de)
DE (1) DE69232859T2 (de)
DK (1) DK0608261T3 (de)
ES (1) ES2182822T3 (de)
FI (1) FI112438B (de)
HU (1) HU227510B1 (de)
PL (2) PL171489B1 (de)
RO (1) RO116199B1 (de)
RU (2) RU2136311C1 (de)
WO (1) WO1993006126A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
PL171489B1 (pl) * 1991-09-13 1997-05-30 Chiron Corp Sposób wytwarzania kompozycji immunogenicznej reagujacej immunologicznie krzyzowo z wieloma izolatami HCV PL
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
EP0671926B1 (de) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunmodulierende peptide
US6762024B2 (en) 1993-04-27 2004-07-13 Innogenetics, S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
EP1421951A3 (de) 1993-05-12 2005-10-05 Chiron Corporation Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
JPH09504534A (ja) 1993-11-04 1997-05-06 インノジェネティクス・エヌ・ブイ Ｃ型肝炎ウイルスの免疫優性ヒトｔ細胞エピトープ
JP3556228B2 (ja) 1994-07-25 2004-08-18 ロシュ ダイアグノスティックス ゲーエムベーハー 複数の抗原を使用した特異的免疫グロブリンの測定
CA2172273A1 (en) 1994-07-29 1996-02-15 Geert Maertens Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
ES2176342T5 (es) 1994-10-21 2010-02-09 Innogenetics N.V. Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos.
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7045363B2 (en) * 1996-05-01 2006-05-16 Fujirebio Inc. Nucleic acid-bound polypeptide method of producing nucleic acid-bound polypeptide and immunoassay using the polypeptide
US6001613A (en) * 1996-05-24 1999-12-14 Board Of Regents Of University Of Nebraska Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid
JP4021493B2 (ja) 1996-11-08 2007-12-12 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、レプリゼンテッド バイ ザ セクレタリー、 デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ Ｃ型肝炎ウイルス様粒子の合成および精製
US6322965B1 (en) * 1997-02-10 2001-11-27 Advanced Life Science Institute, Inc. Chimera antigen peptide
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
DE69841919D1 (de) * 1997-11-06 2010-11-11 Innogenetics Nv Multimere peptide, die auf dem hepatitis c virus hüllprotein basieren, für diagnostische verwendung und für impfzwecke
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6451306B1 (en) 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7157435B2 (en) 1998-04-15 2007-01-02 The Regents Of The University Of California Methods for modulation of the effects of aging on the primate brain
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
US7108855B2 (en) * 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
DK1141315T3 (da) * 1998-12-31 2008-05-19 Novartis Vaccines & Diagnostic Modificerede HIV Env-polypeptider
CA2358385C (en) * 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1535628B1 (de) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-ähnliche teilchen
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
AU6175801A (en) * 2000-07-19 2002-02-05 Univ California Methods for therapy of neurodegenerative disease of the brain
KR20070114209A (ko) 2000-08-17 2007-11-29 트리펩 아베 리바비린 함유 백신 및 이것의 사용 방법
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP1326625A4 (de) 2000-09-13 2005-05-04 Hawaii Biotech Inc Immunogene zusammensetzung von hepatitis c und methoden für ihre verwendung
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP4302513B2 (ja) * 2001-07-05 2009-07-29 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20070073048A1 (en) 2003-05-15 2007-03-29 Ying Lian Hiv polynucleotides and polypeptides derived from botswana mj4
WO2005010035A2 (en) * 2003-07-22 2005-02-03 Branch Andrea D Alternate reading frame polypeptides derived from hepatitis c and methods of their use
WO2005017125A2 (en) * 2003-08-14 2005-02-24 California Institute Of Molecular Medicine Method for isolation and replication of infectious human hepatitis-c virus
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
US7968697B2 (en) * 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
AU2007207544A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
EP2185195A2 (de) * 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
US20100286070A1 (en) * 2007-09-14 2010-11-11 Gert Verheyden Affinity tag
KR102271404B1 (ko) 2007-09-28 2021-07-02 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
EP3604510A1 (de) 2009-03-30 2020-02-05 Portola Pharmaceuticals, Inc. Gegenmittel für faktor-xa-inhibitoren und verfahren zur verwendung davon
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
CN102625712B (zh) 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法
EP3456316A1 (de) 2011-07-06 2019-03-20 GlaxoSmithKline Biologicals S.A. Kationische öl-in-wasser-emulsionen
WO2013006834A1 (en) 2011-07-06 2013-01-10 Novartis Ag Oil-in-water emulsions that contain nucleic acids
WO2013016449A2 (en) 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
KR102143887B1 (ko) 2012-03-16 2020-08-12 유니버시티 헬스 네트워크 Toso 활성을 조절하기 위한 방법 및 조성물
RU2520710C1 (ru) * 2012-12-10 2014-06-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО ЧелГМА Минздравсоцразвития России) Способ прогнозирования персистенции онкогенных типов вируса папилломы человека в цервикальном эпителии
US20150250853A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for modifying the immune response
RU2675108C2 (ru) * 2015-06-15 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Композиция на основе синтетических пептидов и липидов для вакцины против гепатита с
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
EP3365027B1 (de) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
JP2020513838A (ja) 2017-01-04 2020-05-21 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
EP3565834A1 (de) 2017-01-04 2019-11-13 The Research Institute at Nationwide Children's Hospital Antikörperfragmente zur behandlung von biofilmbedingten erkrankungen
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CA3145385A1 (en) 2019-07-08 2021-01-14 Steven D. Goodman Antibody compositions for disrupting biofilms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3400079A1 (de) * 1984-01-03 1985-07-11 Röhm GmbH, 6100 Darmstadt Wasserspreitendes kunststoffmaterial, verfahren zu seiner herstellung u. verwendung als verglasungs- und bedachungsmaterial
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
BR8807310A (pt) * 1987-11-18 1990-03-13 Chiron Corp Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
UA50829C2 (uk) * 1989-03-17 2002-11-15 Чірон Корпорейшн Очищений поліпептид, що містить антиген вірусу гепатиту с, полінуклеотид, вектор, клітини, система експресії, моноклональне антитіло, препарат поліклональних антитіл, нуклеотидна проба, аналітичні набори, спосіб виявлення нуклеїнових кислот, способи імуноаналізу, вакцина, спосіб одержання антитіл
DK0398748T3 (da) * 1989-05-18 2002-03-18 Chiron Corp NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
WO1991004262A1 (en) * 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
ATE318309T1 (de) * 1990-11-03 2006-03-15 Dade Behring Marburg Gmbh Hcv-spezifische peptide, mittel dazu und ihre verwendung
PL171489B1 (pl) * 1991-09-13 1997-05-30 Chiron Corp Sposób wytwarzania kompozycji immunogenicznej reagujacej immunologicznie krzyzowo z wieloma izolatami HCV PL

Also Published As

Publication number Publication date
ES2182822T3 (es) 2003-03-16
RU2136311C1 (ru) 1999-09-10
BG62973B1 (bg) 2000-12-29
JP2008133301A (ja) 2008-06-12
DK0608261T3 (da) 2003-03-17
FI941199A0 (fi) 1994-03-14
JPH06511149A (ja) 1994-12-15
JP2005176853A (ja) 2005-07-07
FI112438B (fi) 2003-12-15
JP2004073207A (ja) 2004-03-11
EP0608261A1 (de) 1994-08-03
US5728520A (en) 1998-03-17
US5670153A (en) 1997-09-23
US5670152A (en) 1997-09-23
EP0608261B1 (de) 2002-11-27
HU9400741D0 (en) 1994-06-28
US6303292B1 (en) 2001-10-16
DE69232859D1 (de) 2003-01-16
HUT67342A (en) 1995-03-28
BG98653A (bg) 1995-05-31
PL171972B1 (pl) 1997-07-31
US5766845A (en) 1998-06-16
ATE228564T1 (de) 2002-12-15
RO116199B1 (ro) 2000-11-30
CA2116764C (en) 1999-12-07
US5756312A (en) 1998-05-26
AU679429B2 (en) 1997-07-03
EP0608261A4 (de) 1995-03-15
JP4353905B2 (ja) 2009-10-28
HU227510B1 (en) 2011-07-28
RU2212899C2 (ru) 2003-09-27
PL171489B1 (pl) 1997-05-30
CA2116764A1 (en) 1993-04-01
WO1993006126A1 (en) 1993-04-01
AU2643692A (en) 1993-04-27
FI941199A (fi) 1994-04-27
JP2002167336A (ja) 2002-06-11

Similar Documents

Publication Publication Date Title
DE69232859T2 (de) Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
HUT73098A (en) Hepatitis c virus (hcv) polypeptides
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
NZ512056A (en) HBV core antigen particles with multiple immunogenic components attached via peptide ligands
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
ATE64601T1 (de) Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
ATA117890A (de) Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
IL128826A0 (en) A crystallizable composition comprising a hepatitis C virus NS3 like polypeptide complexed with a NS4 a-like peptide
IL134982A0 (en) Antibodies which react with polypeptides of cd-44 surface proteins and diagnostic and pharmaceutical compositions prepared therewith
ES8404186A1 (es) "un procedimiento para obtener al menos un polipeptido que presenta la antigenicidad de los antigenos e del virus de la hepatitis b".
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
DE3751834D1 (de) Selbstantigen der primären lebercirrhose
ATE308618T1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
KR910016347A (ko) C형 간염 바이러스에 대한 초면역 글로블린 및 이의 제조방법
DK196689A (da) Ekspression af praes2-proteinet for hepatitis b i methylotrophe gaerarter
FR2676068B1 (fr) Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
FR2550203B1 (fr) Peptides synthetiques immunogenes porteurs d'un epitope caracteristique de l'antigene de surface du virus de l'hepatite b et compositions les contenant
EP0503252A3 (en) Recombinant proteins having the immunoreactivity of hepatitis b virus e antigens (hbeag), method for their production and their application in immunoassays and as vaccines
PL273721A1 (en) Method of obtaining a polypeptide exhibiting antigenic properties in respect to the pre s1 region of hepatitis virus a areole
FR2549725B2 (fr) Fractions polypeptidiques inductrices d'anticorps protecteurs contre des parasites du paludisme et compositions immunogenes les contenant
FR2556971B2 (fr) Fractions polypeptidiques inductrices d'anticorps protecteurs contre des parasites du paludisme et compositions immunogenes les contenant

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

R071 Expiry of right

Ref document number: 608261

Country of ref document: EP